Decoy Therapeutics awards CSO 4,216 restricted shares

Decoy Therapeutics’ chief scientific officer received a new restricted stock award with multi‑year vesting.

Rhea-AI Filing Summary

Decoy Therapeutics Inc. (symbol: DCOY) is the issuer of record for a Form 4 filing submitted to the SEC. Hibner Barbara Louise reported acquisition or exercise transactions in this Form 4 filing.

Decoy Therapeutics Inc. (DCOY) reported that Chief Scientific Officer Barbara Louise Hibner received a grant of 4,216 shares of common stock as restricted stock under the company’s 2026 Equity Incentive Plan on August 31, 2026. 25% of these shares vested immediately, with the balance vesting in approximately equal monthly installments over the next 36 months. Following this award, she directly holds 4,216 shares of common stock.

Insider Trade Summary

Grant/Award: 4,216 shares

Grant/Award 1 txn

Insider Hibner Barbara Louise

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	4,216	$0.00	$0.00

Holdings After Transaction: Common Stock — 4,216 shares (Direct)

Footnotes (1)

1. F1. Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan. 25 percent of the restricted stock vested immediately, and the remainder will vest in approximately equal monthly increments over the next 36 months.

Key Figures

Restricted stock granted: 4,216 shares Grant price per share: $0.00 per share Immediate vesting portion: 25% +2 more

5 metrics

Restricted stock granted 4,216 shares Common stock award to Chief Scientific Officer on August 31, 2026

Grant price per share $0.00 per share Reported acquisition price for restricted stock award

Immediate vesting portion 25% Portion of restricted stock that vested immediately at grant

Remaining vesting period 36 months Restricted stock vesting in approximately equal monthly increments

Shares held after transaction 4,216 shares Direct common stock ownership by Barbara Louise Hibner post-grant

Key Terms

Restricted stock, 2026 Equity Incentive Plan, vested, Chief Scientific Officer

4 terms

Restricted stock financial

"Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan"

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

2026 Equity Incentive Plan financial

"Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan"

vested financial

"25 percent of the restricted stock vested immediately, and the remainder will vest"

Chief Scientific Officer other

"Hibner Barbara Louise serves as Chief Scientific Officer"

FAQ

What insider transaction did DCOY report for Barbara Louise Hibner?

Decoy Therapeutics reported that Chief Scientific Officer Barbara Louise Hibner received a grant of 4,216 shares of restricted common stock on August 31, 2026 under the company’s 2026 Equity Incentive Plan.

How many shares were granted to the DCOY chief scientific officer and at what price?

Barbara Louise Hibner was granted 4,216 shares of Decoy Therapeutics common stock as restricted stock at a reported price of $0.00 per share, reflecting a compensation-related equity award rather than an open‑market purchase.

What is the vesting schedule for the 4,216 restricted shares at DCOY?

Of the 4,216 restricted shares, 25% vested immediately, and the remaining shares will vest in approximately equal monthly installments over the next 36 months, according to the award terms.

What are Barbara Louise Hibner’s DCOY share holdings after this transaction?

After the restricted stock grant, Barbara Louise Hibner directly holds 4,216 shares of Decoy Therapeutics common stock, as reported in the filing.

Was the DCOY restricted stock grant made under a Rule 10b5-1 trading plan?

No. The filing indicates that the Rule 10b5-1 checkbox is not marked, and the transaction is described as a restricted stock grant under the 2026 Equity Incentive Plan, not as a trade under a pre-arranged trading plan.

Under which plan was the DCOY restricted stock granted to the chief scientific officer?

The 4,216 restricted shares granted to Chief Scientific Officer Barbara Louise Hibner were issued under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/02/2026 - 05:47 PM Accepted by SEC EDGAR 09/02/2026 - 05:46 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hibner Barbara Louise

(Last) (First) (Middle)

2450 HOLCOMBE BLVD STE X

(Street)

HOUSTON TEXAS 77021

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Decoy Therapeutics Inc. [ DCOY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/31/2026		A(1)		4,216	A	$0	4,216	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan. 25 percent of the restricted stock vested immediately, and the remainder will vest in approximately equal monthly increments over the next 36 months.

	/s/Mark Rosenblum, as Attorney -in-Fact	09/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)